Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference

Core Insights - Genelux Corporation is a late clinical-stage immuno-oncology company focused on developing next-generation oncolytic immunotherapies for aggressive and difficult-to-treat solid tumors [4] Group 1: Upcoming Events - Thomas Zindrick, President, CEO, and Chairman, along with Matt Pulisic, CFO, will discuss clinical-stage programs and milestones at the Citizens Life Sciences Conference on May 7-8, 2025 [1] - The conversation is scheduled for May 8, 2025, at 1:30 p.m. ET, and a webcast link will be available for the event [2] - The company will also hold one-on-one meetings during the conference for institutional investors interested in engaging with management [3] Group 2: Clinical Trials - Olvi-Vec is currently being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a Phase 3 trial for platinum-resistant/refractory ovarian cancer, and VIRO-25, a Phase 2 trial for non-small-cell lung cancer [4] - Additionally, Olvi-Vec is being assessed in a China-based Phase 1b trial for recurrent small-cell lung cancer [4] Group 3: Company Overview - Genelux's discovery and development efforts are centered around its proprietary CHOICE™ platform, which has led to a library of engineered oncolytic vaccinia virus immunotherapeutic candidates, including Olvi-Vec [4]